Patient Capital Management LLC Has $73.34 Million Stake in Royalty Pharma plc (NASDAQ:RPRX)

Patient Capital Management LLC increased its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 40.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,875,089 shares of the biopharmaceutical company’s stock after purchasing an additional 833,894 shares during the period. Royalty Pharma accounts for about 3.4% of Patient Capital Management LLC’s investment portfolio, making the stock its 10th largest holding. Patient Capital Management LLC owned 0.49% of Royalty Pharma worth $73,344,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Nissay Asset Management Corp Japan ADV raised its stake in shares of Royalty Pharma by 0.7% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 48,481 shares of the biopharmaceutical company’s stock worth $1,238,000 after buying an additional 349 shares in the last quarter. Keene & Associates Inc. lifted its holdings in Royalty Pharma by 1.9% in the 4th quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company’s stock valued at $495,000 after acquiring an additional 370 shares during the last quarter. National Bank of Canada FI boosted its position in shares of Royalty Pharma by 21.8% during the 4th quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 371 shares in the last quarter. Blue Trust Inc. grew its stake in shares of Royalty Pharma by 31.3% in the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 376 shares during the last quarter. Finally, Sanctuary Advisors LLC grew its stake in shares of Royalty Pharma by 0.9% in the 4th quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company’s stock worth $1,068,000 after purchasing an additional 388 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Stock Performance

Shares of RPRX opened at $32.82 on Wednesday. The company has a market capitalization of $18.92 billion, a PE ratio of 22.63, a PEG ratio of 2.31 and a beta of 0.49. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The company’s 50 day moving average price is $32.37 and its 200 day moving average price is $29.86. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.07. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. The business had revenue of $839.00 million for the quarter, compared to the consensus estimate of $724.69 million. Research analysts expect that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a $0.22 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 annualized dividend and a dividend yield of 2.68%. Royalty Pharma’s payout ratio is 47.57%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on RPRX. Citigroup restated a “buy” rating on shares of Royalty Pharma in a report on Friday, March 28th. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Monday. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Royalty Pharma has an average rating of “Buy” and an average price target of $42.50.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.